Gabather AB Company Description

Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases.

It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer’s disease.

The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease.

It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia.

Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden.

Gabather AB (publ)

Country	Sweden
Founded	2014
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	3
CEO	Michael-Robin Witt

Contact Details

Address: Forskargatan 20J Södertälje, 151 36 Sweden
Phone	46 7 36 87 28 39
Website	gabather.com

Stock Details

Ticker Symbol	GABA
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0010869552
SIC Code	2834

Key Executives

Name	Position
Dr. Michael-Robin Witt	Chief Executive Officer and Director
Kristofer Svensson	Chief Financial Officer
Dr. Christine Ryan	Chief Operating Officer
Stefan Rehnmark	C S O